HF Sinclair Corporation Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? HF Sinclair Corporation Common Stock trades at $120.03 (market cap $20.56B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: HF Sinclair Corporation Common Stock is far larger — about 8.9× Recursion Pharmaceuticals Inc's market cap, and HF Sinclair Corporation Common Stock pays a 1.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HF Sinclair Corporation Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DINO | RXRX | |
|---|---|---|
Market Cap | $20.56B | $2.31B |
Volume | 2,204,425 | 40,478,768 |
Sector | Energy | Health |
52-Week High | $120.72 | $6.79 |
52-Week Low | $45.88 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $21.54B | $1.83B |
Dividend Yield | 1.82% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HF Sinclair refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics and renewable fuels businesses.
Read more on DINO →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →